Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Concordia Healthcare Corp. T.CXR.R



TSX:CXR.R - Post by User

Post by marketwatch2011on Oct 30, 2015 9:21am
196 Views
Post# 24242498

Oct 30, 2015 Scotiabank Edge Report

Oct 30, 2015 Scotiabank Edge Report
"We continue to believe AMCo provides important diversification (product and
geographic) and global infrastructure to support additional product
acquisitions. Although highly levered following the close of the transaction, we
believe CXR will be able to fund small tuck-in type product acquisitions while
using its cash flow to pay down its debt.
.
We believe the shares have been oversold due to uncertainty related to the
company's ability to finalize its debt funding and close the deal. With the debt
structure finalized we believe the shares offer an attractive risk/return,
trading at 5.2x 2016E CEPS and a 19% FCF yield. Thus, we maintain our Sector
Outperform rating, with a new $75 price target."
<< Previous
Bullboard Posts
Next >>